Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Diabetes

Weight loss drug reduces risk of diabetes in overweight and obese people

Taking lorcaserin and making lifestyle changes can help prevent diabetes in people who are overweight or obese, study findings indicate.

Obese people

Source: Shutterstock.com

The weight loss drug lorcaserin was associated with a 19% reduced risk of incident diabetes in people with pre-diabetes compared with placebo

The weight loss drug lorcaserin, in addition to lifestyle interventions, may help prevent or improve control of diabetes in people who are overweight or obese, according to trial results published in The Lancet (4 October 2018)[1].

The study included 6,816 people with diabetes, 3,991 people with pre-diabetes and 1,193 people with normal blood sugar levels who were randomly assigned to lorcaserin (10mg twice daily) or placebo.

All participants were overweight or obese with a pre-existing or high risk of atherosclerotic vascular disease and all had access to a lifestyle modification programme.

After a median follow-up of 3.3 years, lorcaserin was associated with a 19% reduced risk of incident diabetes in people with pre-diabetes compared with placebo (8.5% vs. 10.3% incidence, respectively) and a 23% reduction in the risk of diabetes in all participants without diabetes at baseline (6.7% vs. 8.4%).

At one year, compared with placebo, lorcaserin resulted in a reduction of 0.33% in HbA1c levels in patients with diabetes.

Lorcaserin is a selective serotonin 2C receptor agonist that suppresses appetite. It has been available in the United States since 2012 but is not authorised for use in the EU.

“This rigorous and large-scale randomised study demonstrates the potential for improving glycemic control when adding a weight loss agent to a treatment plan,” said lead author Benjamin Scirica from Brigham and Women’s Hospital in Boston, Massachusetts.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205752

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.